Orasis Pharmaceuticals Appoints Julie Speed as Senior Vice President, Head of Strategy and Marketing to Lead Commercial Growth Plan
October 04, 2021 08:00 ET
|
Orasis Pharmaceuticals
HERZLIYA, Israel, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on developing an innovative pharmaceutical solution for the...
Orasis Pharmaceuticals Appoints Industry Veteran, Paul Smith, as President and Chief Operating Officer to Lead the Next Phase of Growth
April 26, 2021 08:00 ET
|
Orasis Pharmaceuticals
HERZLIYA, Israel, April 26, 2021 (GLOBE NEWSWIRE) -- Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on developing an innovative pharmaceutical solution for the...
Orasis Pharmaceuticals Announces Initiation of Phase 3 Clinical Studies of Novel Eye Drop Candidate for the Treatment of Presbyopia
October 28, 2020 09:15 ET
|
Orasis Pharmaceuticals
HERZLIYA, Israel, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on developing an innovative pharmaceutical solution for the...
Orasis Raises $30 Million to Advance the Clinical Development of Novel Treatment for Presbyopia
September 10, 2020 09:30 ET
|
Orasis Pharmaceuticals
HERZLIYA, Israel, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on developing an innovative pharmaceutical solution for the treatment...
Orasis Pharmaceuticals Announces CSF-1 Eye Drop Successfully Met Primary Endpoint in Phase 2b Clinical Study in Presbyopia
October 10, 2019 09:30 ET
|
Orasis Pharmaceuticals
HERZLIYA, Israel, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Orasis Pharmaceuticals LTD., a clinical stage pharmaceutical company developing a corrective eye drop for the treatment of presbyopia as an...
Orasis Announces Initiation of Phase 2b Clinical Study of CSF-1 for the Treatment of Presbyopia
March 27, 2019 09:14 ET
|
Orasis Pharmaceuticals
HERZLIYA, Israel, March 27, 2019 (GLOBE NEWSWIRE) -- Orasis Pharmaceuticals LTD., a clinical stage pharmaceutical company developing a corrective eye drop for the treatment of presbyopia as an...
Orasis Announces Appointments of Richard L. Lindstrom, Eric D. Donnenfeld, and John Berdahl to its Scientific Advisory Board
November 27, 2018 08:00 ET
|
Orasis Pharmaceuticals
HERZLIYA, Israel, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Orasis Pharmaceuticals LTD., a clinical stage pharmaceutical company developing a corrective eye drop for the treatment of presbyopia as an...
Orasis Announces the Appointment of Jeffry Weinhuff as Chairman of the Board of Directors
October 22, 2018 08:00 ET
|
Orasis Pharmaceuticals
HERZLIYA, Israel, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Orasis Pharmaceuticals LTD. a clinical-stage pharmaceutical company developing a corrective eye drop for the treatment of presbyopia as an...
Orasis Pharmaceuticals Closes $13 Million Series B Financing
June 05, 2018 09:30 ET
|
Orasis Pharmaceuticals
HERZLIYA, Israel, June 05, 2018 (GLOBE NEWSWIRE) -- Orasis Pharmaceuticals LTD., a privately-held, clinical-stage pharmaceutical company focused on developing an innovative eye drop for the...